RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+14.02%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.23B
AUM Growth
+$1.23B
(+9%)
Cap. Flow
-$32.4M
Cap. Flow
% of AUM
-2.65%
Top 10 Holdings %
Top 10 Hldgs %
30.12%
Holding
96
New
14
Increased
27
Reduced
30
Closed
13
Top Buys
| 1 |
AbbVie
ABBV
|
$23.6M |
| 2 |
Teladoc Health
TDOC
|
$23M |
| 3 |
Johnson & Johnson
JNJ
|
$18.1M |
| 4 |
Merck
MRK
|
$15.1M |
| 5 |
Royalty Pharma
RPRX
|
$12.5M |
Top Sells
| 1 |
NovoCure
NVCR
|
$50.1M |
| 2 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$25.9M |
| 3 |
LVGO
Livongo Health, Inc. Common Stock
LVGO
|
$23.4M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$20.6M |
| 5 |
IMMU
Immunomedics Inc
IMMU
|
$18.8M |
Sector Composition
| 1 | Healthcare | 97.59% |
| 2 | Industrials | 0.53% |
| 3 | Communication Services | 0% |
| 4 | Consumer Discretionary | 0% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Regeneron Pharmaceuticals
REGN
$59.8B
| $19.3M | 1.58% |
40,000
+17,500
| +78% | +$8.45M |
|
27
Boston Scientific
BSX
$159B
| $19.1M | 1.55% |
530,000
+80,000
| +18% | +$2.88M |
|
|
ALXN
28
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $18.7M | 1.53% |
120,000
-100,000
| -45% | -$15.6M |
|
|
29
Johnson & Johnson
JNJ
$429B
| $18.1M | 1.48% |
+115,000
| New | +$18.1M |
|
30
Centene
CNC
$14.8B
| $17.1M | 1.4% |
285,000
-15,000
| -5% | -$900K |
|
31
Baxter International
BAX
$12.1B
| $16.4M | 1.34% |
205,000
+50,000
| +32% | +$4.01M |
|
32
Abbott
ABT
$230B
| $16.4M | 1.34% |
150,000
-55,000
| -27% | -$6.02M |
|
|
ITCI
33
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $15.9M | 1.3% |
500,000
+25,000
| +5% | +$795K |
|
34
Apellis Pharmaceuticals
APLS
$3.51B
| $15.4M | 1.26% |
270,000
+45,000
| +20% | +$2.57M |
|
35
Esperion Therapeutics
ESPR
$490M
| $15.4M | 1.26% |
592,225
+137,225
| +30% | +$3.57M |
|
36
Iovance Biotherapeutics
IOVA
$800M
| $14.8M | 1.21% |
320,000
-20,000
| -6% | -$928K |
|
37
Alnylam Pharmaceuticals
ALNY
$58.6B
| $14.5M | 1.18% |
111,700
+11,700
| +12% | +$1.52M |
|
38
Neurocrine Biosciences
NBIX
$13.5B
| $14.4M | 1.17% |
150,000
+75,000
| +100% | +$7.19M |
|
39
MacroGenics
MGNX
$121M
| $14.3M | 1.17% |
625,000
-10,711
| -2% | -$245K |
|
40
Sangamo Therapeutics
SGMO
$161M
| $12.8M | 1.05% |
821,888
+146,888
| +22% | +$2.29M |
|
41
Thermo Fisher Scientific
TMO
$183B
| $12.8M | 1.04% |
27,450
-2,550
| -9% | -$1.19M |
|
42
LivaNova
LIVN
$3.09B
| $12.6M | 1.03% |
190,000
-20,000
| -10% | -$1.32M |
|
|
43
Royalty Pharma
RPRX
$15.8B
| $12.5M | 1.02% |
+250,000
| New | +$12.5M |
|
44
HCA Healthcare
HCA
$95.4B
| $12.3M | 1.01% |
75,000
| – | – |
|
|
AERI
45
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $11.5M | 0.94% |
850,000
| – | – |
|
46
Edwards Lifesciences
EW
$47.7B
| $11.4M | 0.93% |
125,000
+5,000
| +4% | +$456K |
|
|
SGEN
47
DELISTED
Seagen Inc. Common Stock
SGEN
| $11.4M | 0.93% |
65,000
-5,000
| -7% | -$876K |
|
48
Xencor
XNCR
$594M
| $11.3M | 0.92% |
259,341
-659
| -0.3% | -$28.8K |
|
49
Becton Dickinson
BDX
$54.3B
| $11.3M | 0.92% |
45,000
+10,000
| +29% | +$2.5M |
|
50
Zimmer Biomet
ZBH
$20.8B
| $10M | 0.82% |
65,000
-17,000
| -21% | -$2.62M |
|